Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rizwan Haq

Showing results (41-50 of 65) with videos related to

Pageof 7
Sort By:
Cancer Cell|March 13, 2013
Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITFRizwan Haq, Jonathan Shoag, Pedro Andreu-Perez, et al.
Nature Genetics|November 24, 2020
Integrated molecular drivers coordinate biological and clinical states in melanomaJake R Conway, Felix Dietlein, Amaro Taylor-Weiner, et al.
Cancer Immunology Research|October 29, 2017
Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition TherapyHyunju Lee, F Stephen Hodi, Anita Giobbie-Hurder, et al.
Journal for Immunotherapy of Cancer|November 13, 2021
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trialPatrick A Ott, Matthew Nazzaro, Kathleen L Pfaff, et al.
Molecular Cell|December 4, 2012
PGC-1 coactivators regulate MITF and the tanning responseJonathan Shoag, Rizwan Haq, Mingfeng Zhang, et al.
Pigment Cell & Melanoma Research|October 10, 2024
Meeting Report From the 2023 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Philadelphia, PA, November 2023Rino S Seedor, Andrew E Aplin, Corine Bertolotto, et al.
Frontiers in Oncology|October 10, 2022
Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastasesAlexander Z Wei, Matan Uriel, Agata Porcu, et al.
Cancer Discovery|April 29, 2014
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitorsDavid J Konieczkowski, Cory M Johannessen, Omar Abudayyeh, et al.
Plos One|July 2, 2014
Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimeticsDennie T Frederick, Roberto A Salas Fragomeni, Aislyn Schalck, et al.
Pigment Cell & Melanoma Research|June 24, 2026
Meeting Report From the 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Amsterdam, the Netherlands, October 2025Andrew E Aplin, Katherina Alsina, Allison S Betof, et al.
Pageof 7

Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Cancer Cell|March 13, 2013
Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITFRizwan Haq, Jonathan Shoag, Pedro Andreu-Perez, et al.
Nature Genetics|November 24, 2020
Integrated molecular drivers coordinate biological and clinical states in melanomaJake R Conway, Felix Dietlein, Amaro Taylor-Weiner, et al.
Cancer Immunology Research|October 29, 2017
Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition TherapyHyunju Lee, F Stephen Hodi, Anita Giobbie-Hurder, et al.
Journal for Immunotherapy of Cancer|November 13, 2021
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trialPatrick A Ott, Matthew Nazzaro, Kathleen L Pfaff, et al.
Molecular Cell|December 4, 2012
PGC-1 coactivators regulate MITF and the tanning responseJonathan Shoag, Rizwan Haq, Mingfeng Zhang, et al.
Pigment Cell & Melanoma Research|October 10, 2024
Meeting Report From the 2023 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Philadelphia, PA, November 2023Rino S Seedor, Andrew E Aplin, Corine Bertolotto, et al.
Frontiers in Oncology|October 10, 2022
Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastasesAlexander Z Wei, Matan Uriel, Agata Porcu, et al.
Cancer Discovery|April 29, 2014
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitorsDavid J Konieczkowski, Cory M Johannessen, Omar Abudayyeh, et al.
Plos One|July 2, 2014
Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimeticsDennie T Frederick, Roberto A Salas Fragomeni, Aislyn Schalck, et al.
Pigment Cell & Melanoma Research|June 24, 2026
Meeting Report From the 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Amsterdam, the Netherlands, October 2025Andrew E Aplin, Katherina Alsina, Allison S Betof, et al.
Pageof 7